Company / Depreciation & Amortization
Viridian Therapeutics, Inc.\DE Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$460.0K
FY2025
5-year range
$120.0K / $540.0K
FY2021-FY2025
Trend
-14.8%
vs FY2024
Sector context
#139 of 168
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's depreciation & amortization of $460,000 is lower than 83% of companies in the Health Care sector (FY2025). Depreciation & Amortization has fluctuated over the past 10 years, ranging from $120,000 in FY2021 to $540,000 in FY2024.
Based on SEC 10-K filings.
$460,000 in FY2025 with a 5-year CAGR of +14.0%.
Improved from $522,000 to $460,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +21.7%
- 5-Year CAGR
- +14.0%
- 10-Year CAGR
- -
Sector benchmark
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +14.0%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 14.8% year-over-year.
- Ranks #139 out of 168 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $460.0K | -14.8% |
| FY2024 | $540.0K | +3.4% |
| FY2023 | $522.0K | +104.7% |
| FY2022 | $255.0K | +112.5% |
| FY2021 | $120.0K | -49.8% |
| FY2020 | $239.0K | -17.0% |
| FY2019 | $288.0K | +2.5% |
| FY2018 | $281.0K | -8.8% |
| FY2017 | $308.0K | -9.7% |
| FY2016 | $341.0K | +85.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026